ReviewDrugs1992
Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.
Review in Drugs, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 83 citations in OpenAlex.
- Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM.Journal of human hypertension · 2007Trial
- Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial.European journal of clinical pharmacology · 2005Trial
- Blood pressure response to conventional and low-dose enalapril in chronic renal failure.British journal of clinical pharmacology · 2003Trial
- Chronopharmacology of enalapril in hypertensive patients.European journal of clinical pharmacology · 1995Trial
- Review
- Untargeted metabolic analysis in serum samples reveals metabolic signature in children with congenital heart failure on enalapril therapy.Frontiers in pediatrics · 2025Article
- The Antihypertensive Effects and Potential Molecular Mechanism of Microalgal Angiotensin I-Converting Enzyme Inhibitor-Like Peptides: A Mini Review.International journal of molecular sciences · 2021Review
- Recent trends in the direct oxyphosphorylation of C-C multiple bonds.RSC advances · 2020Review
- Decarboxylative cross-coupling reactions for P(O)-C bond formation.RSC advances · 2018Review
- Lercanidipine/enalapril combination in the management of obesity-related hypertension.Integrated blood pressure control · 2016Review
- Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence.Patient preference and adherence · 2012Article
- Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.International journal of hypertension · 2012Article
- Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril.Vascular health and risk management · 2008Review
- Fixed-dose combination lercanidipine/enalapril.Drugs · 2007Review
- Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers.Current therapeutic research, clinical and experimental · 2004Article
- Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.Drugs · 2004Review
- Bioavailability prediction based on molecular structure for a diverse series of drugs.Pharmaceutical research · 2004Article
- Clinical pharmacokinetics of vasodilators. Part I.Clinical pharmacokinetics · 1998Review
- Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations.Journal of pharmacokinetics and biopharmaceutics · 1996Article
- ACE inhibitors. Drug interactions of clinical significance.Drug safety · 1995Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enalapril, an angiotensin converting enzyme (ACE) inhibitor usually administered orally once daily, decreases blood pressure by lowering peripheral vascular resistance without increasing heart rate or output. It is effective in lowering blood pressure in all grades of essential and renovascular hypertension. Patients not responding adequately to enalapril monotherapy usually respond with the addition of a thiazide diuretic (or a calcium antagonist or beta-blocker), and rarely require a third antihypertensive agent. Enalapril is at least as effective as other established and newer ACE inhibitors, and members of other antihypertensive drug classes including diuretics, beta-blockers, calcium antagonists and alpha-blockers, but therapy with enalapril may be less frequently limited by serious adverse effects or treatment contraindications than with other drug classes. The most frequent adverse effect limiting all ACE inhibitor therapy in clinical practice is cough. This favourable profile of efficacy and tolerability, and the substantial weight of clinical experience, explain the increasing acceptance of enalapril as a major antihypertensive treatment and supports its use as logical first-line therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.